We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
Werfen

Download Mobile App




Physical Activity and Weight Control Delay Diabetes Onset

By HospiMedica International staff writers
Posted on 12 Nov 2009
A follow-up of a major study has shown that the protective effects of both lifestyle intervention and treatment with metformin last as long as 10 years.

Researchers affiliated with the Diabetes Prevention Program (DPP) at the U.S. More...
National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK; Phoenix, AZ, USA) conducted an extended follow-up of most of the patients from the original DPP study, published in 2002, that compared an intensive lifestyle intervention program with metformin or placebo in 3,234 nondiabetic patients with elevated fasting glucose and impaired glucose tolerance. At the time, the rate of new diabetes fell by 58% with intensive lifestyle intervention and by 31% with metformin only, compared with placebo, over a mean period of 2.8 years. The original study found that compared with metformin, lifestyle intervention, which included diet modification, exercise, and weight-reduction targets, lowered the new diabetes rate by 39%.

The recent 10-year follow up analysis shows that compared to the nonintervention group, patients in the intensive lifestyle intervention group and metformin group, respectively, were 34% and 18% less likely to develop diabetes over 10 years, even after regaining most of the weight initially lost. The benefits of intensive lifestyle intervention were particularly strong in the elderly; those aged 60 and older in the diet and exercise group lowered their rate of developing diabetes by half over 10 years. The researchers will continue to follow the study participants for at least another five years; one goal of the continued follow-up is to determine the impact of the lifestyle and drug interventions on the development of diabetes complications, such as nerve damage and blindness. The study was published online on October 29, 2009, in The Lancet.

"Weight loss is still the most important thing we have to recommend to overweight people at risk for type 2 diabetes,” said lead author William Knowler, M.D., director of the NIDDK. "This study shows that the benefits of even modest weight loss can persist for many years.”

Related Links:

National Institute of Diabetes and Digestive and Kidney Diseases




Gold Member
SARS‑CoV‑2/Flu A/Flu B/RSV Sample-To-Answer Test
SARS‑CoV‑2/Flu A/Flu B/RSV Cartridge (CE-IVD)
Antipsychotic TDM Assays
Saladax Antipsychotic Assays
Open Stapler
PROXIMATE Linear Cutter
Head Rest
Medifa 61114_3
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to HospiMedica.com and get access to news and events that shape the world of Hospital Medicine.
  • Free digital version edition of HospiMedica International sent by email on regular basis
  • Free print version of HospiMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of HospiMedica International in digital format
  • Free HospiMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Surgical Techniques

view channel
Image: The fiber in the brain implant is less than half a millimeter thick (Photo courtesy of Peter Aagaard Brixen)

Brain Implant Records Neural Signals and Delivers Precise Medication

Neurological diseases such as epilepsy involve complex interactions across multiple layers of the brain, yet current implants can typically stimulate or record activity from only a single point.... Read more

Patient Care

view channel
Image: The revolutionary automatic IV-Line flushing device set for launch in the EU and US in 2026 (Photo courtesy of Droplet IV)

Revolutionary Automatic IV-Line Flushing Device to Enhance Infusion Care

More than 80% of in-hospital patients receive intravenous (IV) therapy. Every dose of IV medicine delivered in a small volume (<250 mL) infusion bag should be followed by subsequent flushing to ensure... Read more

Business

view channel
Image: Medtronic’s intent to acquire CathWorks follows a 2022 strategic partnership with a co-promotion agreement for the FFRangio System (Photo courtesy of CathWorks)

Medtronic to Acquire Coronary Artery Medtech Company CathWorks

Medtronic plc (Galway, Ireland) has announced that it will exercise its option to acquire CathWorks (Kfar Saba, Israel), a privately held medical device company, which aims to transform how coronary artery... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.